Spots Global Cancer Trial Database for osimertinib
Every month we try and update this database with for osimertinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | NCT06142617 | Non Small Cell ... Immune Checkpoi... EGFR Exon 21 Mu... | Pembrolizumab, ... Osimertinib | 18 Years - | Peking Union Medical College Hospital | |
| Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm | NCT05546866 | Non-small Cell ... | Osimertinib | 18 Years - 130 Years | AstraZeneca | |
| Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M | NCT02841579 | Non-Small Cell ... | Osimertinib | 18 Years - | MedSIR | |
| Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | NCT03543683 | Non-Small Cell ... Non-small Cell ... EGFR T790M | Osimertinib Aspirin | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | NCT03485326 | Non-small Cell ... | - | AstraZeneca | ||
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | NCT02917993 | Lung Cancer | Itacitinib Osimertinib | 18 Years - | Incyte Corporation | |
| Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma | NCT06014827 | Lung Non-Small ... Stage IV Lung C... | Biospecimen Col... Computed Tomogr... Osimertinib Positron Emissi... Stereotactic Bo... Survey Administ... | 18 Years - | City of Hope Medical Center | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | NCT04720976 | Solid Tumor NSCLC | JAB-3312 Binimetinib Pembrolizumab Sotorasib Osimertinib | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | NCT06194448 | Lung Cancer | Osimertinib Cisplatin or Ca... Radiation | 18 Years - 130 Years | AstraZeneca | |
| A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases | NCT03497767 | Metastatic Non ... | Osimertinib Stereotactic Ra... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) | NCT03532698 | Non-Small Cell ... Non-small Cell ... EGFR T790M | Aspirin Osimertinib | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | NCT04233021 | Non Small Cell ... Leptomeningeal ... Brain Metastase... EGFR Activating... | Osimertinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Afatinib Osimertinib Sequencing NIS | NCT03370770 | Carcinoma, Non-... | Afatinib Osimertinib | 18 Years - | Boehringer Ingelheim | |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | NCT04181060 | Advanced Lung N... Metastatic Lung... Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C... | Bevacizumab Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Osimertinib | 18 Years - | National Cancer Institute (NCI) | |
| Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | NCT02759835 | Lung Adenocarci... Lung Neoplasms | osimertinib Local Ablative ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | NCT05017025 | Advanced Lung N... Metastatic Lung... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Aurora A Kinase... Osimertinib | 18 Years - | M.D. Anderson Cancer Center | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | NCT05163249 | Carcinoma, Non-... | Osimertinib Savolitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | NCT05020769 | Non-small Cell ... | SI-B001 Osimertinib | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC | NCT03784599 | Carcinoma, Non-... | Trastuzumab emt... Osimertinib | 18 Years - | The Netherlands Cancer Institute | |
| Osimertinib for NSCLC With Uncommon EGFR Mutations | NCT05421936 | Carcinoma, Non-... Genes, erbB-1 | Osimertinib | 18 Years - 99 Years | Sheba Medical Center | |
| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations | NCT05801029 | Non-Small Cell ... | Osimertinib Amivantamab | 18 Years - 130 Years | AstraZeneca | |
| A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib | NCT03239340 | EGFR Mutation P... | Osimertinib | 18 Years - 130 Years | AstraZeneca | |
| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations | NCT05801029 | Non-Small Cell ... | Osimertinib Amivantamab | 18 Years - 130 Years | AstraZeneca | |
| A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations | NCT06362980 | NSCLC | BPI-1178 Osimertinib | 18 Years - | National Cancer Center, China | |
| Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC | NCT05215951 | Lung Cancer | osimertinib | 18 Years - | AstraZeneca | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI | NCT04829019 | Neurocognitive | Osimertinib and... Osimertinib | 18 Years - | Sun Yat-sen University | |
| Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | NCT02803203 | Non-small Cell ... EGFR-mutant Lun... | osimertinib Bevacizumab | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) | NCT02856893 | NSCLC | Osimertinib Gefitinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. | NCT06296745 | Leptomeningeal ... | Pemetrexed | 18 Years - 75 Years | Guangzhou Medical University | |
| Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis | NCT04148898 | Leptomeningeal ... Non-small Cell ... EGFR Activating... | Osimertinib Bevacizumab | 18 Years - 80 Years | Second Affiliated Hospital of Nanchang University | |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) | NCT05629234 | Cancer | Osimertinib | 18 Years - 99 Years | AstraZeneca | |
| Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer | NCT03831932 | Advanced Lung N... Metastatic Lung... Stage IV Lung C... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Osimertinib Positron Emissi... Telaglenastat H... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | NCT04870190 | NSCLC | Almonertinib Osimertinib | 18 Years - | Shanghai Chest Hospital | |
| A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | NCT02099058 | Advanced Solid ... | Osimertinib Nivolumab Telisotuzumab v... Telisotuzumab v... Erlotinib | 18 Years - | AbbVie | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC | NCT02908750 | Non Small Cell ... | Fexofenadine ta... Osimertininb ta... | 18 Years - 130 Years | AstraZeneca | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | NCT06319950 | Lung Cancer, No... | Furmonertinib Osimertinib | 18 Years - 80 Years | Taizhou Hospital | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | NCT05261399 | Carcinoma Non-Small-Cell ... | Savolitinib Osimertinib Pemetrexed Cisplatin Carboplatin | 18 Years - 130 Years | AstraZeneca | |
| Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer | NCT02520778 | Advanced Lung N... Metastatic Lung... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung N... | Navitoclax Osimertinib | 18 Years - | National Cancer Institute (NCI) | |
| Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | NCT05281406 | NSCLC Stage III... NSCLC Stage IV | Osimertinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Goethe University | |
| Osimertinib for Advanced EGFR-positive NSCLC Patients | NCT05037331 | EGFR Positive N... Non Small Cell ... | 21 Years - 99 Years | National University Hospital, Singapore | ||
| First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting | NCT04391283 | Carcinoma, Non-... | Osimertinib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein | NCT06093503 | Non-Small Cell ... | Telisotuzumab V... Osimertinib Cisplatin Carboplatin Pemetrexed | 18 Years - | AbbVie | |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) | NCT05629234 | Cancer | Osimertinib | 18 Years - 99 Years | AstraZeneca | |
| Pharmacokinetic Boosting of Osimertinib | NCT03858491 | Non Small Cell ... | Cobicistat | 18 Years - | Academisch Ziekenhuis Maastricht | |
| HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | NCT04676477 | Non-Small Cell ... | HER3-DXd HER3-DXd Osimertinib Osimertinib HER3-DXd HER3-DXd Osimertinib | 18 Years - | Daiichi Sankyo | |
| Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | NCT03778229 | Carcinoma | osimertinib savolitinib placebo | 18 Years - | AstraZeneca | |
| BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations | NCT06032936 | NSCLC | BBP-398 osimertinib | 18 Years - 99 Years | LianBio LLC | |
| Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | NCT06436144 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Osimertinib | 18 Years - 80 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC | NCT04141644 | Non-Small Cell ... | Ipilimumab Osimertinib | 18 Years - | University of Utah | |
| Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | NCT04721015 | Advanced Solid ... Non Small Cell ... | ABBV-637 Docetaxel Osimertinib | 18 Years - | AbbVie | |
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | NCT05120349 | Non-Small Cell ... | Osimertinib Placebo | 18 Years - | AstraZeneca | |
| TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | NCT05948813 | NSCLC EGFR Activating... Brain Metastase... | TY-9591 Osimertinib | 18 Years - 80 Years | TYK Medicines, Inc | |
| Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations | NCT03191149 | Advanced Lung N... Recurrent Lung ... Stage IIIB Lung... Stage IV Lung N... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Osimertinib | 18 Years - | National Cancer Institute (NCI) | |
| Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | NCT03891615 | Lung Cancer | Niraparib Osimertinib | 18 Years - | Massachusetts General Hospital | |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | NCT04285671 | Metastatic Lung... Refractory Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Necitumumab Osimertinib Quality-of-Life... Questionnaire A... Trastuzumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer | NCT03460275 | Non-small Cell ... | Osimertinib Mes... | 18 Years - 75 Years | Sun Yat-sen University | |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | NCT04479306 | Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alisertib Osimertinib Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | NCT05382728 | NSCLC EGFR Activating... | TY-9591 placebo Osimert... Osimertinib placebo TY-9591 | 18 Years - 80 Years | TYK Medicines, Inc | |
| A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib | NCT03239340 | EGFR Mutation P... | Osimertinib | 18 Years - 130 Years | AstraZeneca | |
| Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations | NCT05103605 | Non Small Cell ... | Osimertinib | 18 Years - | AstraZeneca | |
| Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC | NCT04988607 | Lung Cancer | Osimertinib Bevacizumab Osimertinib | 18 Years - | Guangdong Association of Clinical Trials | |
| First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer | NCT03804580 | Lung Cancer | osimertinib | 18 Years - | Vestre Viken Hospital Trust | |
| Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases | NCT02971501 | Metastatic Lung... Metastatic Mali... Stage IV Lung C... | Bevacizumab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Osimertinib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | NCT03567642 | Lung Cancer | Osimertinib Platinum Etoposide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | NCT02803203 | Non-small Cell ... EGFR-mutant Lun... | osimertinib Bevacizumab | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | NCT04575415 | NSCLC | Bevacizumab Erlotinib Gefitinib Icotinib Afatinib Dacomitinib Osimertinib | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | NCT05163249 | Carcinoma, Non-... | Osimertinib Savolitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases | NCT03497767 | Metastatic Non ... | Osimertinib Stereotactic Ra... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC | NCT04105153 | EGFR Positive N... | 18 Years - | Thoraxklinik-Heidelberg gGmbH | ||
| Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery | NCT03433469 | Stage I Non-Sma... Stage IA Non-Sm... Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Osimertinib Therapeutic Con... | 18 Years - | University of California, San Francisco | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
